Issue #2 of “Rheuminate” is now out! We CATCH up with some new data from the Canadian Early Arthritis Cohort, highlight a network meta-analysis that compares safety among the growing family of JAKi, and feature a comparative analysis of the relative benefits and risks of upadacitinib compared to adalimumab. Read Issue #2 here.

Rheuminate is a monthly selection of new publications clinically relevant to the SMART community of Canadian rheumatologists.

In this second issue, we consider the following topics:

  • Glucocorticoid use in the Canadian Early Arthritis Cohort
  • Systematic review and network meta-analysis of CV and VTE risk with JAKi
  • Comparative benefit-risk analysis of upadacitinib and adalimumab

>> Read Rheuminate Issue #2 here.

View all issues of Rheuminate online at smartrheum.org/rheuminate